Form 4 holding
Chief Operating Officer
Keros Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 60,000
- Estimated value
- $2,640,600
- Report date
- 18 Feb 2025
- Price
- $44.01
- Ownership
- Direct
Christopher Rovaldi
Insider Reports History
- Reporting-owner location
- Cambridge, MA
- Latest reporting-owner signature
-
/s/ Keith Regnante, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Christopher Rovaldi
Insider Reports Filed by Christopher Rovaldi
4
KROS
Keros Therapeutics, Inc.
- Report period
- 18 Feb 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 19 Feb 2025, 16:15
- Role
- Chief Operating Officer
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 13 Feb 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Feb 2024, 20:38
- Role
- CHIEF OPERATING OFFICER
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 16 Feb 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Feb 2023, 15:19
- Role
- Chief Operating Officer
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 06 Apr 2022
- Transactions
- 3
- Transaction value
- -$84,672
- Accepted by SEC
- 08 Apr 2022, 16:21
- Role
- Chief Operating Officer
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 01 Apr 2022
- Transactions
- 7
- Transaction value
- -$35,851
- Accepted by SEC
- 05 Apr 2022, 16:31
- Role
- Chief Operating Officer
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 01 Feb 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Feb 2022, 15:45
- Role
- Chief Operating Officer
- Next action
- Open filing details
3
KROS
Keros Therapeutics, Inc.
- Report period
- 01 Feb 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 03 Feb 2022, 15:37
- Role
- Chief Operating Officer
- Next action
- Open filing details